Bleomycin combination chemotherapy in the management of testicular neoplasia
N = 90
- Population
- Patients with stage II or stage III germinal neoplasia of the testis or extragonadal primary tumours; 70 had stage III disease
- Design
- Uncontrolled series: 83 patients with stage II or III germinal neoplasia of the testis and 7 patients with extragonadal primaries treated with bleomycin plus vinblastine or a five-drug programme (bleomycin plus cyclophosphamide, vincristine, methotrexate and 5-fluorouracil). Response reported for the stage III patients.
- Arms
- Bleomycin combination programmes (experimental, n = 90): Bleomycin plus vinblastine, or bleomycin plus cyclophosphamide, vincristine, methotrexate and 5-fluorouracil
- People
- Samuels ML, senior author Johnson DE
Show the numbers
| Endpoint | Analysis | Bleomycin combination programmes | Control | Effect |
|---|---|---|---|---|
| ORRStage III patients (70)Complete plus partial response | finalSamuels 1975 | 75% | — | 53 responses: 22 complete and 31 partial. Complete responders had mean survival of 100+ weeks with 3 deaths; partial responders and non-responders 38 and 33 weeks (p < 0.01). Pneumonitis from bleomycin occurred in 5 of 90 evaluable patients. |
| Endpoint | Analysis | Bleomycin combination programmes | Control | Effect |
|---|---|---|---|---|
| ORRStage III patients (70)Complete plus partial response | finalSamuels 1975 | 75% | — | 53 responses: 22 complete and 31 partial. Complete responders had mean survival of 100+ weeks with 3 deaths; partial responders and non-responders 38 and 33 weeks (p < 0.01). Pneumonitis from bleomycin occurred in 5 of 90 evaluable patients. |